(DOXA) Doxa - Ratings and Ratios
Exchange: ST • Country: Sweden • Currency: SEK • Type: Common Stock • ISIN: SE0005624756
DOXA: Real Estate, Properties, Investments, Development, Management
Doxa AB (publ) is a Swedish real estate investment company with a diversified portfolio spanning multiple asset classes. Its properties include offices, sports and event venues, hotels, restaurants, commercial spaces, warehouses, logistics facilities, and residential units. The company also engages in contracting, project development, and property management. Headquartered in Malmö, Sweden, Doxa AB was established in 1987 and operates both domestically and internationally.
As of the latest data, Doxa AB (ST:DOXA) has a market capitalization of 520.64M SEK. The stock currently trades at 0.36 SEK, with a price-to-book ratio of 0.16, indicating a significant discount to its book value. The price-to-sales ratio stands at 26.70, reflecting a premium valuation relative to its revenue. The return on equity is -28.76%, highlighting profitability challenges. The companys shares are categorized under the GICS Sub Industry: Life Sciences Tools & Services.
From a technical perspective, the stocks short-term moving averages (SMA 20: 0.41, SMA 50: 0.45) are above the current price, while the long-term SMA 200 (1.06) is significantly higher. This suggests a bearish trend. The average trading volume over the past 20 days is 6,476,228 shares, with an ATR of 0.05, indicating low volatility.
3-Month Forecast: Based on the technical and fundamental data, Doxa AB (ST:DOXA) is expected to remain under pressure in the near term. The declining SMA trend and negative return on equity suggest limited upside potential. However, the low ATR indicates that price fluctuations will likely remain modest. The stock is projected to trade within a narrow range, potentially testing support levels near its current price of 0.36 SEK.Additional Sources for DOXA Stock
DOXA Stock Overview
| Market Cap in USD | 49m |
| Sector | Real Estate |
| Industry | Real Estate Services |
| GiC Sub-Industry | Life Sciences Tools & Services |
| IPO / Inception |
DOXA Stock Ratings
| Growth 5y | -69.1% |
| Fundamental | -51.2% |
| Dividend | 0.0% |
| Rel. Strength Industry | -87.9 |
| Analysts | - |
| Fair Price Momentum | 0.37 SEK |
| Fair Price DCF | - |
DOXA Dividends
No Dividends PaidDOXA Growth Ratios
| Growth Correlation 3m | -74.1% |
| Growth Correlation 12m | -97.8% |
| Growth Correlation 5y | -22.7% |
| CAGR 5y | -24.21% |
| CAGR/Max DD 5y | -0.25 |
| Sharpe Ratio 12m | -1.02 |
| Alpha | -92.69 |
| Beta | 0.14 |
| Volatility | 71.72% |
| Current Volume | 3854.9k |
| Average Volume 20d | 3833.9k |
As of March 14, 2025, the stock is trading at SEK 0.42 with a total of 3,854,937 shares traded.
Over the past week, the price has changed by +5.32%, over one month by +7.36%, over three months by -22.91% and over the past year by -87.92%.
No, based on ValueRay Fundamental Analyses, Doxa (ST:DOXA) is currently (March 2025) a stock to sell. It has a ValueRay Fundamental Rating of -51.20 and therefor a negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of DOXA as of March 2025 is 0.37. This means that DOXA is currently overvalued and has a potential downside of -11.9%.
Doxa has no consensus analysts rating.
According to ValueRays Forecast Model, DOXA Doxa will be worth about 0.4 in March 2026. The stock is currently trading at 0.42. This means that the stock has a potential downside of -4.76%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 0.4 | -4.8% |